Johna Lucas Selected Research

Psychological Sexual Dysfunctions (Sexual Arousal Disorder)

1/2022	Safety Profile of Bremelanotide Across the Clinical Development Program.
11/2021	Failure of a Meta-analysis: A Commentary on Glen Spielmans's "Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder in Women'".
1/2021	The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.
11/2019	Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
11/2019	Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.
1/2019	Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.
3/2017	Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants.
1/2011	Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen.
9/2005	Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Johna Lucas Research Topics

Disease

9	Psychological Sexual Dysfunctions (Sexual Arousal Disorder) 01/2022 - 09/2005
3	Nausea 01/2022 - 11/2019
3	Flushing 01/2022 - 11/2019
3	Headache (Headaches) 01/2022 - 11/2019
1	Hyperpigmentation 01/2022
1	Injection Site Reaction 01/2022
1	Body Weight (Weight, Body) 01/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Hypertension (High Blood Pressure) 01/2017

Drug/Important Bio-Agent (IBA)

8	bremelanotideIBA 01/2022 - 01/2017
3	Testosterone (Sustanon)FDA Link 01/2022 - 09/2005
2	Melanocortin Receptors (Melanocortin Receptor)IBA 01/2022 - 03/2017
1	Pharmaceutical PreparationsIBA 11/2019
1	Hormones (Hormone)IBA 03/2017
1	Melanocyte-Stimulating Hormones (MSH)IBA 03/2017
1	Peptides (Polypeptides)IBA 03/2017
1	thiamine triphosphorate (TTP)IBA 01/2011